Year : 2021 | Volume
: 34 | Issue : 1 | Page : 10--14
Mitigation of in-hospital risk of coronavirus disease 2019: Experience from a haematology–oncology and stem cell transplant setting
Suvir Singh1, Davinder Paul2, Kunal Jain2, Jagdeep Singh2
1 Clinical Haematology and Stem Cell Transplantation, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
2 Department of Medical Oncology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India
Background. Coronavirus disease 2019 (Covid-19) was first described in December 2019 and has evolved into an ongoing global pandemic. Cancer patients on chemotherapy are immunocompromised and are at the highest risk of Covid-19-related complications. We describe our experience with the management of haematology–oncology and stem cell transplant (SCT) patients receiving curative chemotherapy in a hospital with a high influx of Covid-19 patients.
Methods. We did a prospective observational study at a 99-bedded cancer centre of a tertiary care teaching hospital from April 2020 to September 2020. Preventive measures taken were categorized as follows: (i) staff: screening, mandatory use of personal protective equipment (PPE), risk stratification of potential exposure and testing and isolation as needed; (ii) patients: mandatory viral polymerase chain reaction testing, segregation of positive and untested patients and testing of family members; and (iii) environment: mandatory regular cleaning, visitor restriction, telemedicine services and reassignment of priority to clinic visits. Treatment of the underlying conditions was continued with added precautions.
Results. A total of 54 patients were included in the analysis, including 48 with haematological malignancies and 6 for stem cell therapy. Preventive measures were universally applied, and chemotherapy with a curative intent was initiated as per protocol. Three patients were detected to have Covid-19 infection before admission and one after the institution of chemotherapy. Nine patients died after the first cycle of chemotherapy, 2 due to severe Covid-19-related illness and 7 due to complications of chemotherapy or disease progression.
Conclusions. In the wake of the Covid-19 pandemic, treatment for haematological malignancies must continue while balancing the risk of Covid-19 infections. Our report emphasizes the effectiveness of measures such as hand hygiene, social isolation, patient segregation, use of masks and PPE and universal pre-treatment testing for Covid-19 in reducing the risk of infection in a high-risk clinical setting.
Department of Medical Oncology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab
|How to cite this article:|
Singh S, Paul D, Jain K, Singh J. Mitigation of in-hospital risk of coronavirus disease 2019: Experience from a haematology–oncology and stem cell transplant setting.Natl Med J India 2021;34:10-14
|How to cite this URL:|
Singh S, Paul D, Jain K, Singh J. Mitigation of in-hospital risk of coronavirus disease 2019: Experience from a haematology–oncology and stem cell transplant setting. Natl Med J India [serial online] 2021 [cited 2021 Sep 25 ];34:10-14
Available from: http://www.nmji.in/article.asp?issn=0970-258X;year=2021;volume=34;issue=1;spage=10;epage=14;aulast=Singh;type=0